Table 3.
Sex stratified by APOE-ε4 carrier status. Demographic and imaging biomarker comparisons in EOAD, EOnonAD, and CN cohorts split by sex and further stratified by APOE-ε4 carrier status. (A) EOAD male APOE-ε4 carriers vs. male non-carriers and EOAD female APOE-ε4 carriers vs. female non-carriers. (B) EOnonAD male APOE-ε4 carriers vs. male non-carriers and EOnonAD female APOE-ε4 carriers vs. female non-carriers. (C) CN male APOE-ε4 carriers vs. male non-carriers and CN female APOE-ε4 carriers vs. female non-carriers. Whole FBB SUVR = global amyloid uptake; FTP MetaROI SUVR, Braak 12, Braak 34, Braak 56 = tau uptake.
| (A)EOAD | ||||||
|---|---|---|---|---|---|---|
| Female | Male | |||||
| APOE-ε4+ Carrier | Non-carrier | p-value | APOE-ε4+ Carrier | Non-carrier | p-value | |
| N | 56 | 54 | 54 | 40 | ||
| Age, years, mean (SD) | 62.8 (4.5) | 61.8 (3.8) | 0.3 | 62.3 (4.0) | 61.5 (4.6) | 0.4 |
| Education, years, mean (SD) | 15.5 (2.6) | 15.6 (2.5) | 0.9 | 15.1 (2.3) | 15.5 (2.2) | 0.3 |
| MMSE (SD) | 22.8 (4.5) | 20.4 (5.1) | 0.01 | 22.2 (0.5) | 21.5 (5.6) | 0.5 |
| APOE-ε4+ (%) | 51% | 57% | ||||
| Whole FBB SUVR, mean, (SD) | 1.56 (0.2) | 1.65 (0.1) | <0.001 | 1.54 (0.2) | 1.53 (0.2) | 0.8 |
| FTP MetaROI SUVR, mean (SD) | 2.13 (0.4) | 2.24 (0.4) | 0.2 | 1.93 (0.5) | 2.05 (0.4) | 0.2 |
| BRAAK 12 SUVR, mean (SD) | 1.62 (0.2) | 1.51 (0.2) | 0.004 | 1.51 (0.2) | 1.48 (0.2) | 0.5 |
| BRAAK 34 SUVR, mean (SD) | 1.91 (0.4) | 1.98 (0.3) | 0.3 | 1.76 (0.4) | 1.82 (0.3) | 0.4 |
| BRAAK 56 SUVR, mean (SD) | 1.83 (0.5) | 1.98 (0.4) | 0.09 | 1.70 (0.5) | 1.81 (0.4) | 0.2 |
| Hippocampal Vol, cm 3 , mean (SD) | 2.34 (0.3) | 2.42 (0.3) | 0.09 | 2.26 (0.3) | 2.34 (0.2) | 0.2 |
| (B)EOnonAD | ||||||
| Female | Male | |||||
| APOE-ε4+ Carrier | Non-carrier | p-value | APOE-ε4+ Carrier | Non-carrier | p-value | |
| N | 11 | 13 | 17 | 26 | ||
| Age, years, mean (SD) | 61.0 (7.6) | 61.0 (5.6) | 0.9 | 62.6 (5.8) | 61.0 (6.0) | 0.4 |
| Education, years, mean (SD) | 14.4 (2.0) | 15.4 (2.2) | 0.3 | 16.2 (2.6) | 15.7 (2.9) | 0.6 |
| MMSE (SD) | 24.8 (6.4) | 23.4 (6.1) | 0.6 | 26.6 (2.7) | 26.6 (2.1) | 0.1 |
| APOE-ε4+ (%) | 46% | 40% | ||||
| Whole FBB SUVR, mean, (SD) | 1.04 (0.09) | 1.00 (0.05) | 0.2 | 1.01 (0.08) | 1.00 (0.06) | 0.3 |
| FTP MetaROI SUVR, mean (SD) | 1.27 (0.4) | 1.28 (0.4) | 0.1 | 1.24 (0.3) | 1.15 (0.07) | 0.2 |
| BRAAK 12 SUVR, mean (SD) | 1.18 (0.2) | 1.19 (0.2) | 0.9 | 1.19 (0.2) | 1.15 (0.1) | 0.4 |
| BRAAK 34 SUVR, mean (SD) | 1.22 (0.4) | 1.21 (0.3) | 0.1 | 1.19 (0.3) | 1.12 (0.06) | 0.2 |
| BRAAK 56 SUVR, mean (SD) | 1.15 (0.3) | 1.13 (0.2) | 0.8 | 1.11 (0.3) | 1.04 (0.05) | 0.2 |
| Hippocampal Vol, cm 3 , mean (SD) | 2.65 (0.2) | 2.64 (0.4) | 0.9 | 2.41 (0.5) | 2.52 (0.3) | 0.4 |
| (C)CN | ||||||
| Female | Male | |||||
| APOE-ε4+ Carrier | Non-carrier | p-value | APOE-ε4+ Carrier | Non-carrier | p-value | |
| N | 24 | 26 | 8 | 16 | ||
| Age, years, mean (SD) | 59.7 (5.2) | 60.8 (6.1) | 0.5 | 58.0 (6.8) | 60.1 (6.2) | 0.5 |
| Education, years, mean (SD) | 16.3 (1.8) | 16.4 (2.5) | 0.9 | 17.3 (3.0) | 17.5 (2.0) | 0.8 |
| MMSE, mean (SD) | 29.4 (0.7) | 29.2 (0.9) | 0.3 | 29.4 (0.7) | 29.3 (0.7) | 0.8 |
| APOE-ε4+ (%) | 48% | 33% | ||||
| Whole FBB SUVR, mean, (SD) | 1.04 (0.07) | 1.02 (0.06) | 0.2 | 1.08 (0.2) | 1.01 (0.1) | 0.2 |
| FTP MetaROI SUVR, mean (SD) | 1.14 (0.06) | 1.15 (0.05) | 0.4 | 1.31 (0.4) | 1.15 (0.06) | 0.2 |
| BRAAK 12 SUVR, mean (SD) | 1.13 (0.1) | 1.15 (0.07) | 0.4 | 1.29 (0.2) | 1.16 (0.07) | 0.06 |
| BRAAK 34 SUVR, mean (SD) | 1.11 (0.06) | 1.12 (0.04) | 0.5 | 1.24 (0.3) | 1.13 (0.06) | 0.2 |
| BRAAK 56 SUVR, mean (SD) | 1.07 (0.05) | 1.08 (0.04) | 0.5 | 1.11 (0.1) | 1.06 (0.06) | 0.3 |
| Hippocampal Vol, cm 3 , mean (SD) | 2.78 (0.2) | 2.77 (0.3) | 0.8 | 2.75 (0.3) | 2.81 (0.3) | 0.6 |